In another blow to big pharma, India's Supreme Court rejects Novartis's Glivec patent plea
India’s Supreme Court has issued its eagerly anticipated judgment in the long-running Glivec patent case. Upholding previous decisions, the court ruled that the country’s patent office was right to refuse a patent to Novartis for its anti-cancer…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe now